- Home
- MBWM vs EVMN Comparison
MBWM vs EVMN Comparison
Compare MBWM & EVMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MBWM | EVMN |
|---|---|---|
| Founded | 1997 | 2020 |
| Country | United States | United States |
| Employees | N/A | 48 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 884.4M | 825.5M |
| IPO Year | 1997 | N/A |
Fundamental Metrics
Financial Performance| Metric | MBWM | EVMN |
|---|---|---|
| Price | $53.05 | $23.01 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 10 |
| Target Price | ★ $55.67 | $43.88 |
| AVG Volume (30 Days) | 92.9K | ★ 381.8K |
| Earning Date | 04-21-2026 | 06-11-2026 |
| Dividend Yield | ★ 3.08% | N/A |
| EPS Growth | ★ 10.95 | N/A |
| EPS | ★ 1.32 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $20.28 | N/A |
| Revenue Next Year | $4.67 | N/A |
| P/E Ratio | $39.89 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $42.17 | $13.89 |
| 52 Week High | $55.77 | $33.20 |
Technical Indicators
Market Signals| Indicator | MBWM | EVMN |
|---|---|---|
| Relative Strength Index (RSI) | 57.65 | 46.84 |
| Support Level | $49.25 | $21.32 |
| Resistance Level | $54.90 | $23.08 |
| Average True Range (ATR) | 1.25 | 1.25 |
| MACD | 0.20 | 0.13 |
| Stochastic Oscillator | 92.01 | 51.43 |
Price Performance
Historical ComparisonAbout MBWM Mercantile Bank Corporation
Mercantile Bank Corp operates as a bank holding company. It offers various commercial banking services to individuals, businesses, governmental units, and other institutions. These services include deposit products such as checking, savings, and term certificate accounts and lending products such as commercial, residential mortgage, and installment loans. The company generates revenue from interest and dividends earned on loans, securities, and other financial instruments.
About EVMN Evommune Inc.
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.